In a recent global patent disputes, the Madras High Court has pronounced a ruling concerning the ongoing patent dispute in the United States involving Pfizer’s drug, VYNDAMAX (also known as TAFAMIDIS), which is used to treat a rare heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM).
The case is in focus due to the high stakes involved, as Pfizer holds a patent for VYNDAMAX, which is a formulation of TAFAMIDIS, a drug that stabilizes transthyretin (TTR) protein in the heart, which reduces the life-threatening effects of ATTR-CM. Pfizer’s patent rights on the drug have been contested in several jurisdictions, but this ruling in the Madras High Court is particularly noteworthy, as it reflects the broader international implications of the ongoing patent conflict.
In its order, the Madras High Court emphasized the importance of protecting intellectual property, especially for life-saving drugs like VYNDAMAX in pharma sector. The court ruled that Pfizer’s patent for TAFAMIDIS must be upheld in India, despite challenges from generic manufacturers. This ruling reinforces Pfizer’s exclusive rights over the formulation, production or distribution of VYNDAMAX in the Indian market.
The Madras High Court’s decision is groundbreaking for the global pharmaceutical industry, particularly in the realm of patent enforcement. The ongoing patent dispute in the other countries like United States has sparked heated debates over access to affordable medicines versus protecting the intellectual property rights of pharmaceutical companies. VYNDAMAX is considered a breakthrough in the treatment of a condition that severely impacts the heart, and its exclusivity remains a point of contention in markets where generic alternatives are being sought.
Pfizer has expressed its satisfaction with the ruling, stating that it affirms the company’s commitment to innovation and patient care. The company further emphasized that the decision will help ensure that VYNDAMAX remains available to those who need it while protecting the intellectual property rights of pharmaceutical innovators.
Although, it is expected that this ruling will have limited direct effect on markets outside of India, but it does signify the growing importance of patent protection in the global pharmaceutical landscape. Stakeholders, including patients, healthcare providers, and competitors, are keenly awaiting further developments in this high-profile case.
As the patent battle continues across borders, it remains to be seen how other jurisdictions will respond to similar challenges regarding VYNDAMAX and whether further legal actions will alter the course of the ongoing dispute.
infringement
Longi sues JinkoSolar for infringement of new patent technology
Longi, has filed lawsuits against JinkoSolar for their patent infringement, both the companies are leading players in the solar industry. The legal actions have been initiated in both countries China and the United States.
In China, Longi has filed the lawsuit at the Jinan Intermediate People’s Court in Shandong and requested an immediate halt to the manufacturing, sales, and offers to sell the allegedly infringing products and other related activities to it. The Court has accepted the case, with an expected trial date of March 20.
In the United States, the lawsuit was filed at the U.S. District Court for the Eastern District of Texas, alleging patent infringement of Jinko Solar’s TOPCon and multiple other unspecified photovoltaic module products.
Longi claims that JinkoSolar has infringed upon its intellectual property (IP) related to solar technology, specifically patents concerning the production and design of solar cells and panels. This dispute comes out as both companies are at the forefront of solar technology innovation. The patents plays a critical role in protecting advancements in the highly competitive solar energy sector.
The lawsuits highlight the ongoing tensions in the renewable energy industry, where patent disputes are becoming increasingly common as companies rush to secure a competitive edge in the rapidly growing market for solar energy products. In these types of cases, the outcome can impact product sales, partnerships, and overall market positioning for the companies involved.
It remains to be seen how these lawsuits will unfold, but they signal the importance of intellectual property rights in the clean energy sector.
In China, Longi has filed the lawsuit at the Jinan Intermediate People’s Court in Shandong and requested an immediate halt to the manufacturing, sales, and offers to sell the allegedly infringing products and other related activities to it. The Court has accepted the case, with an expected trial date of March 20.
In the United States, the lawsuit was filed at the U.S. District Court for the Eastern District of Texas, alleging patent infringement of Jinko Solar’s TOPCon and multiple other unspecified photovoltaic module products.
Longi claims that JinkoSolar has infringed upon its intellectual property (IP) related to solar technology, specifically patents concerning the production and design of solar cells and panels. This dispute comes out as both companies are at the forefront of solar technology innovation. The patents plays a critical role in protecting advancements in the highly competitive solar energy sector.
The lawsuits highlight the ongoing tensions in the renewable energy industry, where patent disputes are becoming increasingly common as companies rush to secure a competitive edge in the rapidly growing market for solar energy products. In these types of cases, the outcome can impact product sales, partnerships, and overall market positioning for the companies involved.
It remains to be seen how these lawsuits will unfold, but they signal the importance of intellectual property rights in the clean energy sector.
“Ratan Tata” is a well-known trademark: Delhi High Court
The recent judgement issued by Delhi High Court on February 7 says that the name “Ratan Tata” is a well-known trademark which needs to be protected as per law.
Justice Mini Pushkarna made the observation while hearing a trademark suit filed by Tata Group and Sir Ratan Tata Trust against misusing the Tata brand, trademarks and the name of late Ratan Tata. [Sir Ratan Tata Trust Vs Dr. Rajat Srivastava].
On February 7, 2025, the court prohibited Rajat Srivastava, from hosting an event under the name “Ratan Tata Icon Award.” The court also restricted him from using the name and photograph of the late Ratan Tata for any purpose, including conferring any awards. The judgement is to protect the reputation and legacy of Ratan Tata, a highly respected business figure and philanthropist. The injunction likely stems from concerns over the misuse of his name and image in a manner that could potentially mislead or cause confusion about his endorsement of such events.
Generally, a well-known trademark is a mark that has achieved such a high degree of recognition among the public. It’s a mark that’s so famous and recognizable that its mere presence evokes the brand in the minds of consumers.
The lawsuit filed by Tata Group and the Sir Ratan Tata Trust emphasized the long-standing reputation and legacy of the Tata name, which has been a symbol of trust, quality, and ethical business practices in India for over 150 years. They argued that the unauthorized use of the Tata name and Ratan Tata’s image, particularly in the organization of events and awards, misled the public into thinking the Tata entities were endorsing them.
Rajat Srivastava and his organization, allegedly exploited the Tata brand’s goodwill by charging nomination fees for the event and promoting it across social media platforms. This created confusion among the public, making them believe the event was connected to or endorsed by the Tata Trusts. Despite the Tata Trusts issuing a takedown notice to stop such promotions, the defendants allegedly continued advertising the event, prompting the legal action.
The court ruled in favor of the Tata Group and the Sir Ratan Tata Trusts, granting them a permanent injunction against Rajat Srivastava and his organization. This means that the defendants are now permanently prohibited from using the Tata name, trademarks, or Ratan Tata’s image in any future events, promotions, or activities. However, the court directed the defendants to file an affidavit confirming their commitment to not engage in such activities going forward.
While the plaintiffs, Tata Group and the Tata Trusts, expressed satisfaction with the court’s ruling, they chose to waive any claims for damages or legal costs. This decision emphasizes that their main focus is on protecting the integrity of the Tata brand and preventing future misuse, rather than seeking any financial compensation.